Literature DB >> 23733471

Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.

Stefan Weiler1, Christoph Seger, Hartwig Pfisterer, Eva Stienecke, Florian Stippler, René Welte, Michael Joannidis, Andrea Griesmacher, Romuald Bellmann.   

Abstract

Caspofungin pharmacokinetics was assessed in 27 critically ill patients, including 7 on continuous venovenous hemofiltration (CVVH), 8 on continuous venovenous hemodialysis (CVVHD), and 13 not requiring continuous renal replacement therapy (CRRT). Caspofungin exposure during CRRT was very similar to that of the control group and comparable to that in healthy volunteers. Caspofungin clearance by CRRT was very low. Therefore, the standard dosage of caspofungin is probably adequate for critically ill patients undergoing CVVH or CVVHD.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23733471      PMCID： PMC3719695          DOI： 10.1128/AAC.00335-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration.

Authors:  Kiyotaka Hirata; Takahiko Aoyama; Yoshiaki Matsumoto; Futosi Ogawa; Hiroshi Yamazaki; Arimichi Kikuti; Yasuhiro Yamamoto
Journal:  Yakugaku Zasshi       Date:  2007-05       Impact factor: 0.302

3.  Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation.

Authors:  Stéphanie Ruiz; Emmanuelle Papy; Daniel Da Silva; Patrick Nataf; Laurent Massias; Michel Wolff; Lila Bouadma
Journal:  Intensive Care Med       Date:  2008-09-16       Impact factor: 17.440

4.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients.

Authors:  Satoshi Kishino; Keiko Ohno; Tsuyoshi Shimamura; Hiroyukisatoru Furukawatodo
Journal:  Clin Transplant       Date:  2004-12       Impact factor: 2.863

Review 6.  Pharmacokinetic issues for antibiotics in the critically ill patient.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

7.  Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.

Authors:  Michael Joannidis; Jordan Kountchev; Markus Rauchenzauner; Nicola Schusterschitz; Hanno Ulmer; Andreas Mayr; Romuald Bellmann
Journal:  Intensive Care Med       Date:  2007-06-12       Impact factor: 17.440

8.  Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.

Authors:  T H Nguyen; T Hoppe-Tichy; H K Geiss; A C Rastall; S Swoboda; J Schmidt; M A Weigand
Journal:  J Antimicrob Chemother       Date:  2007-05-24       Impact factor: 5.790

Review 9.  Effects of renal replacement therapy on antimicrobial therapy.

Authors:  Matthias G Vossen; Florian Thalhammer
Journal:  Curr Clin Pharmacol       Date:  2013-02-01

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  20 in total

Review 1.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.

Authors:  Qian-Ting Yang; Ya-Jing Zhai; Lu Chen; Tao Zhang; Yan Yan; Ti Meng; Lei-Chao Liu; Li-Mei Chen; Xue Wang; Ya-Lin Dong
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

Review 4.  [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-03-20       Impact factor: 0.840

5.  Low Caspofungin Exposure in Patients in Intensive Care Units.

Authors:  Kim C M van der Elst; Anette Veringa; Jan G Zijlstra; Albertus Beishuizen; Rob Klont; Petra Brummelhuis-Visser; Donald R A Uges; Daan J Touw; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Doripenem Treatment during Continuous Renal Replacement Therapy.

Authors:  M G Vossen; J M Wenisch; A Maier-Salamon; A Fritsch; K Saria; C Zuba; S Jilch; R Lemmerer; M Unger; U Jaehde; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.

Authors:  M G Vossen; D Knafl; M Haidinger; R Lemmerer; M Unger; S Pferschy; W Lamm; A Maier-Salamon; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.

Authors:  Claire Roger; Steven C Wallis; Laurent Muller; Gilbert Saissi; Jeffrey Lipman; Roger J Brüggemann; Jean-Yves Lefrant; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

Review 9.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

10.  Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy.

Authors:  Soo Min Jang; Grayson Hough; Bruce A Mueller
Journal:  Blood Purif       Date:  2018-06-14       Impact factor: 2.614
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.